Clinical TrialJul 31, 2026, 07:32 AM
Medicus Pharma Receives UAE IND for Teverelix® Phase 2a Study
AI Summary
Medicus Pharma Ltd. announced that the UAE Department of Health – Abu Dhabi granted Investigational New Drug (IND) authorization for its PRECISION-E2 Phase 2a clinical study. This study will evaluate Teverelix® in approximately 84 women with moderate-to-severe symptomatic endometriosis, marking a significant regulatory milestone for the company's women's health strategy. The study is designed as a genomics-guided precision medicine program to identify patients most likely to benefit from the long-acting GnRH antagonist.
Key Highlights
- UAE DOH granted IND authorization for PRECISION-E2 Phase 2a clinical study.
- Study evaluates Teverelix® in approximately 84 women with moderate-to-severe symptomatic endometriosis.
- PRECISION-E2 is a prospective, randomized, placebo-controlled Phase 2a study.
- The study aims to integrate genomic information for a precision medicine approach.
- Teverelix® is a next-generation, long-acting GnRH antagonist.
- The study will explore four treatment groups, including 60 mg and 90 mg doses.
Price Impact
More from MDCX